COVID-19 and Pulmonary Hypertension: An Interesting Dynamic

Area of Science:

• Cardiology and Pulmonology
• Infectious Diseases
• Critical Care Medicine

Background:

• The relationship between COVID-19 and pulmonary hypertension (PH) has been a growing area of research since 2020.
• While PH pathophysiology is understood, COVID-19's multisystemic effects, particularly on the cardiopulmonary system, are still emerging.
• Investigative interest focuses on the interplay between SARS-CoV-2 infection and PH development and outcomes.

Purpose of the Study:

• To review the current understanding of the interplay between COVID-19 and pulmonary hypertension.
• To examine risk factors for developing PH post-SARS-CoV-2 infection.
• To discuss outcomes for patients with pre-existing PH who contract COVID-19 and explore potential therapeutic applications of PH medications in COVID-19 patients.

Main Methods:

• Literature review and synthesis of existing research on COVID-19 and pulmonary hypertension.
• Analysis of proposed mechanisms linking SARS-CoV-2 infection to PH.
• Discussion of clinical outcomes and therapeutic strategies.

Main Results:

• Several factors, including cytokine storm, ARDS, and fibrotic lung changes, are implicated in increased PH risk after COVID-19.
• Outcomes for patients with pre-existing PH diagnosed with COVID-19 require further investigation.
• Off-label use of PH medications for COVID-19 cardiopulmonary complications is under consideration.

Conclusions:

• COVID-19 presents potential risks for developing pulmonary hypertension.
• Further research is needed to clarify the outcomes of COVID-19 in patients with pre-existing PH.
• Investigating the utility of pulmonary hypertension therapies in managing COVID-19 complications holds promise.